FDA Approved: EMEND — Original Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved EMEND (fosaprepitant dimeglumine) from Merck Sharp & Dohme LLC as an original New Drug Application (NDA022023).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• EMEND (aprepitant)

Snippet

ORIG AP for EMEND (FOSAPREPITANT DIMEGLUMINE)